Table 1.
Baseline clinical and laboratory characteristic of the entire treated mCRPC patients prior to the [177Lu]Lu-PSMA-617 therapy
| Parameters | Values |
|---|---|
| Patients (n) | 61 |
| Age (mean ± SD) years | 71.6 ± 6.9 |
| Weight (mean ± SD) kilogram | 81 ± 12.7 |
| [177Lu]Lu-PSMA-617 MBq | 7321 ± 562 |
| Karnofsky score (n) | |
| < 80% | (20) 36.1% |
| ≥ 80% | (39) 63.9% |
| ECOG Index (n) | |
| 0 | (4) 6.5% |
| 1 | (53) 86.8% |
| 2 | (4) 6.5% |
| Patients received blood transfusion before first therapy (n) | (5) 8% |
| *PSA μg/L | 70.7 (1.0–4890) |
| Hb (mean ± SD) g/dL | 11.8 ± 1.93 |
| Thrombocyte (mean ± SD) g/L | 283 ± 67 |
| *Leucocyte g/L | 6.38 (2.94–13.7) |
| *Creatinine mg/dL | 0.92 (0.66–1.74) |
| *LDH U/L | 202 (127–1943) |
| *AP U/L | 76.5 (27–752) |
| Previous treatments (n) | |
| Enzalutamide/abiraterone | (46) 75.4% |
| Docetaxel/cabazitaxel | (42) 68.9% |
|
Xofigo® No hormone- or chemo- or Xofigo® therapy |
(18) 29.5% (6) 9.8% |
| Metastatic lesions (n) | |
| Bone | (16) 26.2% |
| Local recurrence + lymph node | (9) 14.8% |
| Bone + lymph node | (34) 55.7% |
| Bone + lymph node + liver | (6) 9.8% |
| Bone + lymph node + lung | (5) 8.1% |
SD standard deviation; (*) data with no Gaussian distribution, presented in median (range); PSA prostatic specific antigen, Hb hemoglobin, LDH lactate dehydrogenase, AP alkaline phosphatase